Staley Capital Advisers Inc Phathom Pharmaceuticals, Inc. Transaction History
Staley Capital Advisers Inc
- $2.12 Billion
- Q1 2024
A detailed history of Staley Capital Advisers Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Staley Capital Advisers Inc holds 10,000 shares of PHAT stock, worth $103,000. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$103,000
Previous $91,000
16.48%
% of portfolio
0.01%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.9 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$36 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.3 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $404M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...